Clinical Trials Logo

Hyperlipoproteinemias clinical trials

View clinical trials related to Hyperlipoproteinemias.

Filter by:

NCT ID: NCT02189837 Completed - Clinical trials for Primary Hyperlipidemia and Mixed Dyslipidemia

Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody

FLOREY
Start date: July 8, 2014
Phase: Phase 3
Study type: Interventional

This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.

NCT ID: NCT02186483 Completed - Diabetes Clinical Trials

Clinical Trial to Investigate the Pharmacokinetics Drug Interaction Between Metformin and Rosuvastatin

Start date: August 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to investigate the pharmacokinetic drug interaction between Metformin and Rosuvastatin in healthy male volunteers.

NCT ID: NCT02153073 Completed - Hyperlipidemia Clinical Trials

Evaluation of the Safety and Efficacy of Long-term Use of Omega-3 Fatty Acid Ethyl Esters

Start date: May 29, 2013
Phase:
Study type: Observational

The purpose of this study is to evaluate the safety and efficacy of long-term use of granular capsule formulation of omega-3 fatty acid ethyl esters (Lotriga Granular Capsules) in patients with hyperlipidemia in daily medical practice

NCT ID: NCT02135029 Completed - Hyperlipidemia Clinical Trials

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

SPIRE-SI
Start date: June 2014
Phase: Phase 3
Study type: Interventional

This study is a multicenter, double blinded, active and placebo controlled randomized clinical trial to demonstrate a superior lipid lowering effect of Bococizumab (PF-04950615; RN316) compared to placebo in subjects who are statin intolerant.

NCT ID: NCT02100839 Completed - Clinical trials for Hypercholesterolemia

Safety Study of AEM-28 to Treat Refractory Hypercholesterolemia

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of the first part of this study is to determine the safety and tolerability of a single dose of AEM-28, an apolipoprotein E mimetic, in subjects with high total cholesterol who are otherwise healthy subjects. The pharmacokinetics and pharmacodynamics of AEM-28 will also be evaluated. The second part of this study will be a multiple ascending dose evaluation of AEM-28 in patients with refractory hypercholesterolemia. AEM-28 has demonstrated significant lipid lowering activity and positive effects on the artery wall. AEM-28 is being developed for the treatment of homozygous familial hypercholesterolemia.

NCT ID: NCT02100514 Completed - Hyperlipidemia Clinical Trials

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Primary Hyperlipidemia or Mixed Dyslipidemia At Risk Of Cardiovascular Events

SPIRE-LL
Start date: October 28, 2014
Phase: Phase 3
Study type: Interventional

This study is a multicenter, double-blind, randomized study to access the efficacy, safety and tolerability of Bococizumab (PF-04950615; RN316) in subjects with hyperlipidemia receiving background statin therapy.

NCT ID: NCT02098278 Completed - Clinical trials for Hypertriglyceridemia

Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia

Start date: March 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and chylomicron triglyceride levels, as well as postprandial total and chylomicron triglyceride clearance. This is a single-blind study. All patients will receive placebo for 1 week, and CAT-2003 for 12 weeks during the 13 week treatment period.

NCT ID: NCT02069106 Withdrawn - Clinical trials for Mixed Hyperlipoproteinemia

Efficacy Study of Daily Pro-Omega LDL for Low-Density Lipoprotein Cholesterol and Triglyceride Reduction

PrOteCT
Start date: February 2014
Phase: Phase 4
Study type: Interventional

Pro-Omega LDL reduces low-density lipoprotein cholesterol and triglycerides in subjects with mixed hyperlipoproteinemia.

NCT ID: NCT02056847 Completed - Clinical trials for HbA1c Level Associated With Lipid Compositions

to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia

SIPHON
Start date: September 2013
Phase: Phase 4
Study type: Interventional

Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG). H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4 µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)

NCT ID: NCT02044627 Completed - Hyperlipidemia Clinical Trials

Single Radiolabeled Dose Study to Investigate the Absorption, Metabolism and Excretion of [14C]-ETC-1002

Start date: December 2013
Phase: Phase 1
Study type: Interventional

This Phase 1 study will assess the mass balance recover of carbon-14 (14C) labelled ETC-1002 and the routes and rates of excretion of [14C]-ETC-1002